Summary - Funding Rounds

Founding Date

1978

Investors

Par Pharmaceutical is a subsidiary of Endo International

Par Pharmaceutical Income Statement

Annual

USDFY, 2013FY, 2014

Revenue

1.1b246.1m

Revenue growth, %

R&D expense

100.8m

General and administrative expense

155.2m

Operating expense total

383.5m

Depreciation and amortization

184.3m

EBIT

(65.4m)(29.8m)

EBIT margin, %

(6%)(12%)

Interest expense

95.5m26.0m

Interest income

87.0k50.0k

Income tax expense

(61.2m)(17.7m)

Net Income

(105.9m)(32.5m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015

Revenue

267.3m289.1m295.4m336.1m332.2m

R&D expense

27.2m34.6m28.5m26.5m28.6m

General and administrative expense

39.4m50.9m43.9m42.0m54.9m

Operating expense total

106.1m128.5m111.0m170.7m93.9m

Depreciation and amortization

54.2m44.1m39.1m38.6m36.5m

EBIT

(24.7m)(34.2m)(17.5m)(32.9m)45.9m

EBIT margin, %

(9%)(12%)(6%)(10%)14%

Interest expense

23.4m25.5m27.5m27.7m40.0m

Interest income

14.0k14.0k2.0k15.0k

Income tax expense

(18.8m)(24.2m)(18.1m)(22.4m)442.0k

Net Income

(29.3m)(39.4m)(26.9m)(37.6m)5.4m

Par Pharmaceutical Balance Sheet

Annual

USDFY, 2013FY, 2014

Cash

130.1m244.4m

Accounts Receivable

143.3m158.7m

Inventories

117.3m154.7m

Current Assets

465.6m653.1m

PP&E

127.3m217.3m

Goodwill

849.7m1.0b

Total Assets

2.6b3.0b

Accounts Payable

31.2m80.0m

Short-term debt

21.5m14.5m

Current Liabilities

259.0m277.8m

Total Debt

21.5m

Additional Paid-in Capital

686.6m808.6m

Retained Earnings

(138.4m)(243.9m)

Total Equity

547.4m561.1m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

4.8 x5.4 x

Par Pharmaceutical Cash Flow

Annual

USDFY, 2013FY, 2014

Net Income

(105.9m)(32.5m)

Depreciation and Amortization

207.6m50.3m

Accounts Receivable

(64.6m)(42.0m)

Cash From Operating Activities

113.0m(28.6m)

Cash From Investing Activities

(12.2m)(2.0b)

Cash From Financing Activities

(7.6m)1.8b

Interest Paid

86.2m14.0m

Income Taxes Paid

14.9m

Free Cash Flow

95.6m(18.3m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015

Net Income

(65.8m)(39.4m)(66.3m)(103.9m)25.7m

Depreciation and Amortization

153.5m50.7m97.1m142.1m101.7m

Accounts Receivable

(30.6m)42.0m(6.9m)(81.6m)112.3m

Inventories

(14.5m)(20.3m)(23.5m)

Cash From Operating Activities

79.6m89.1m27.5m(10.2m)100.6m

Cash From Investing Activities

(7.5m)(490.9m)(496.3m)(503.4m)(79.3m)

Cash From Financing Activities

(5.0m)492.2m494.6m492.2m(111.0m)

Interest Paid

50.2m13.6m47.3m63.0m63.9m

Income Taxes Paid

12.1m7.7m40.3m42.1m41.3m

Free Cash Flow

66.8m75.9m6.3m(39.6m)81.4m
Report incorrect company information

Par Pharmaceutical Employee Rating

3.1107 votes
Culture & Values
3.1
Work/Life Balance
3.3
Senior Management
2.8
Salary & Benefits
3.9
Career Opportunities
2.9
Source